Moderna’s Coronavirus Vaccine Shows Signs of Early Progress

The first Covid-19 vaccine to be tested in humans appears safe and able to generate coronavirus-killing antibodies in test subjects, Moderna said Monday. The findings are just a sample from its phase one clinical trial in which eight volunteers who were given two doses of the vaccine in March developed antibodies on par with recovered virus patients.

"The data couldn't have been better," Moderna CEO Stephane Bancel said, calling the results "a very good sign that we make an antibody that can stop the virus from replicating." Chief Medical Officer Tal Zaks said the figures "substantiate our belief that mRNA-1273 has potential to prevent Covid-19 and advance our ability to select a dose for pivotal trials."

Side effects seen in the trial included fatigue, fever, muscle pains and headache, and all of the symptoms resolved within a day. Moderna is moving into phase two of its clinical trials to further study its effectiveness, and it plans to test thousands of patients in phase three this summer.

QUICKTAKE ON SOCIAL:

QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.

[errorproductions]

I hope they do find a vaccine sitting in my house feels like sitting in a jail cell

[chiefdouble]

I remember when trump said: "we should have a vaccine by the end of the year"